SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing heightened market activity as the community anticipates the upcoming Goliath mainnet launch. Traders are actively debating whether this momentum represents a sustainable bullish breakout or another cycle of volatility, with many monitoring whale movements and network infrastructure preparations while maintaining strong conviction in long-term staking.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is seeing significant market interest as community members speculate on its integration with AI authentication and its role as a potential standard for human verification. Traders are actively tracking institutional treasury accumulation and the broader strategic involvement of high-profile figures in the AI sector, driving discussions around its long-term adoption and price potential.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is experiencing significant momentum as the community focuses on its upcoming halving and growing institutional interest, with many investors highlighting its role as a leading decentralized AI infrastructure network. Discussions are heavily centered on the potential for long-term growth driven by scarcity, the ecosystem's unique incentive structure for AI subnets, and active accumulation ahead of expected supply changes.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is experiencing heightened volatility and intense community debate as investors weigh the project's long-term potential in agentic AI against significant recent downward price pressure. While some see the current levels as a compelling accumulation opportunity driven by robust fundamentals and institutional interest, others are expressing frustration over stagnant performance and the lasting impact of the ASI merger and recent token liquidations.

Shell Plc engages in the business of producing oil and natural gas. It operates through the following segments: Integrated Gas, Upstream, Marketing, Chemicals and Products, Renewables and Energy Solutions, and Corporate. The Integrated Gas segment includes liquefied natural gas, and conversion of natural gas into gas-to-liquids fuels. The Upstream segment focuses on exploration and extraction of crude oil, natural gas, and natural gas liquids. The Marketing segment is involved in mobility, lubricants, and sectors and decarbonization businesses. The Chemicals and Products segment consists of chemicals manufacturing plants with marketing network and refineries, which turn crude oil and other feedstocks into a range of oil products. The Renewables and Energy Solutions segment provides renewable power generation, marketing, trading, and optimizing power and pipeline gas, as well as carbon credits and digitally enabled customer solutions. The Corporate segment covers non-operating activities supporting Shell such as holdings, treasury organization, self-insurance activities, and headquarters and central functions. The company was founded in February 1907 and is headquartered in London, the United Kingdom.

Shell Plc - ADR (Representing - Ordinary Shares)

Shell Plc is capturing significant investor interest as global energy markets react to intensifying geopolitical volatility and potential supply chain disruptions. The community is actively discussing the company's role as a dominant global LNG trader, its massive share buyback programs, and strategic portfolio shifts, including recent asset divestments and expansion in high-return energy projects.

Dogelon Mars

Dogelon Mars is trending as the community debates its long-term potential and viability amid persistent price stagnation and frustration over the lack of major developments. Despite the vocal criticism of its performance, some holders remain committed, pointing to the project's OG meme coin status and speculating on future catalysts to drive interest.

ONEOK, Inc. engages in gathering, processing, fractionating, transporting, storing and marketing of natural gas. It operates through the following segments: Natural Gas Gathering and Processing, Natural Gas Liquids and Natural Gas Pipelines. The Natural Gas Gathering and Processing segment offers midstream services to producers in North Dakota, Montana, Wyoming, Kansas and Oklahoma. The Natural Gas Liquids segment owns and operates facilities that gather, fractionate, treat and distribute NGLs and store NGL products, in Oklahoma, Kansas, Texas, New Mexico and the Rocky Mountain region, which includes the Williston, Powder River and DJ Basins, where it provides midstream services to producers of NGLs and deliver those products to the two market centers, one in the Mid-Continent in Conway, Kansas and the other in the Gulf Coast in Mont Belvieu, Texas. The Natural Gas Pipelines segment provides transportation and storage services to end users. The company was founded in 1906 and is headquartered in Tulsa, OK.

Oneok Inc.

ONEOK is actively trending as investors analyze the company's recent strategic acquisitions and their integration within its midstream operations, which remain a primary focus for the market. The community is heavily engaged in debating the stock's long-term growth potential and dividend consistency, while watching for technical breakouts amid fluctuations in natural gas liquids volume and market-wide energy sector volatility.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is seeing intense investor focus as the company's NDA for CTx-1301 was officially accepted by the FDA, setting a PDUFA date of May 31, 2026. The community is buzzing over the potential for an upcoming U.S. patent grant and the possibility of a buyout, with many long-term holders actively accumulating shares and debating the stock's potential for significant upside as it nears commercialization.

The RealReal, Inc. is an online marketplace for consigned luxury goods, which engages in the consignment of luxury goods across multiple categories, including women's, men's, kids, jewelry, watches, home, and art. It sells pieces from designers such as Chanel, Christian Louboutin, Gucci, Hermes, Louis Vuitton, Prada, Celine, Jimmy Choo, Burberry, and Valentino. The company was founded by Julie Wainwright and Marcy Carmack on March 29, 2011 and is headquartered in San Francisco, CA.

Therealreal Inc

The RealReal is currently a focal point for investors debating its path to profitability, with the community split between those optimistic about AI-driven operational efficiencies and others concerned by persistent cash burn and high institutional short interest. Discussions are heavily centered on whether the company's recent earnings milestones represent a sustainable turnaround or if the stock remains a tactical play for institutional traders.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

The 401jK community is actively rallying around a "Resist and Retire" narrative, using viral memes and grassroots IRL raids to mock the traditional financial system. Investors are showing strong conviction through high staking participation and community-driven content, positioning the project as a grassroots alternative to conventional retirement planning.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Yeah  you&#39;re right I will unblock him.  In theory the future best ALS treatment will most likely be a combo therapy. But  $BCLI partnered with titan $CTLT  has dozens of better alternatives. It is sketchy how therapeutic solutions international inc since 2007 and has  not even starting a phased trial for ALS. Chaim is right to not be dragged down with TSI. Nurown which has actually met empirically collected data of stat sig in phase 3 for a genetic ALS  about 41% of cases.  $TSOI pumpers keep pretending that Allogenic  justifies going in blind  despite risks of host rejection, disease transfer, &amp; infection. I think most problematic to ALS is allogenic cannot  guarantee a consistent quality of cells and Dixon has no registered human trials of Jadicell.

Yosemite

Frank Tsang

Carl Johnson

$BCLI My advice to all longs, do not block people who are attacking Nurown and want to obliterate the company.  Detract them, debunk them, put them in their right place, set the record straight.   If you block them you cannot set the record straight and that&#39;s how they win!!  Now let&#39;s make May  Nurown ALS awareness Month and make ALS treatable in 1 year not 10.

StockTwits Web

Brainstorm Cell Therapeutics, Inc.

Catalent Inc.

Therapeutic Solutions International Inc

Yeah  you're right I will unblock him.  In theory the future best ALS treatment will most likely be a combo therapy. But  

  has dozens of better alternatives. It is sketchy how therapeutic solutions international inc since 2007 and has  not even starting a phased trial for ALS. Chaim is right to not be dragged down with TSI. Nurown which has actually met empirically collected data of stat sig in phase 3 for a genetic ALS  about 41% of cases.  

 pumpers keep pretending that Allogenic  justifies going in blind  despite risks of host rejection, disease transfer, & infection. I think most problematic to ALS is allogenic cannot  guarantee a consistent quality of cells and Dixon has no registered human trials of Jadicell.

@Samtosemi I&#39;d disagree with a blanket statement of allogenic and lack of consistent quality.  Although challenging, Mesoblast has achieved it.  Brainstorm however has struggled in this area, highlighted by their embarrassing performance in the adcom in regards to CMC.

$TSOI $BCLI $MESO
Correct.
Although I wouldn’t go as far as “embarrassing”.
Every biotechnology company experiences challenges.
Meet challenges;  persevere.  
$MESO did. $BCLI is in the process of, and $TSOI owns exclusive multi-patented international rights for Use of most potent Allogeniec MSC ever discovered, having filed 23 USPTO Use and 1 monster manufacturing patent.

All (3) companies have and will likely continue to experience success. 
And many lives may be saved moving forward as a result.  

Biotechnology/Immunotherapy IS the very bright future of medicine. 🧬

StockTwits for iOS

TradersTrader

 I'd disagree with a blanket statement of allogenic and lack of consistent quality.  Although challenging, Mesoblast has achieved it.  Brainstorm however has struggled in this area, highlighted by their embarrassing performance in the adcom in regards to CMC.

mfglola

@mfglola The reason being is that Allogenic comes from other people and you will never get the same conditions twice which would further complicate CMC. I also think the objections to Nurown&#39;s CMC were absolutely unqualified and asking proprietary information during the adcom. I noticed they werent specific either  just from a place of defending the rejection in defiance of act for ALS more repetitively rejecting the post hoc finding of stat sig with bad comparisons even using horoscope.

 The reason being is that Allogenic comes from other people and you will never get the same conditions twice which would further complicate CMC. I also think the objections to Nurown's CMC were absolutely unqualified and asking proprietary information during the adcom. I noticed they werent specific either  just from a place of defending the rejection in defiance of act for ALS more repetitively rejecting the post hoc finding of stat sig with bad comparisons even using horoscope.

@Samtosemi I don&#39;t think the adcom was asking for proprietary information.  I think the problem was due to the development of nurown.  Nurown was initially developed with the idea that delivering increased levels of BDNF, GDNF, VEGF, and HGF would provide a therapeutic benefit to various neurological disorders.   However, from the phase 3 we only really ever see data on VEGF.  Much of the benefit seems to come from other factors that would be secreted from regular stem cells.  So if secretion of other factors is important to nurown&#39;s mechanism of action, it would seem reasonable that they would be part of the quality inspection.  This is what adcom was getting at.

 I don't think the adcom was asking for proprietary information.  I think the problem was due to the development of nurown.  Nurown was initially developed with the idea that delivering increased levels of BDNF, GDNF, VEGF, and HGF would provide a therapeutic benefit to various neurological disorders.   However, from the phase 3 we only really ever see data on VEGF.  Much of the benefit seems to come from other factors that would be secreted from regular stem cells.  So if secretion of other factors is important to nurown's mechanism of action, it would seem reasonable that they would be part of the quality inspection.  This is what adcom was getting at.

You and allegedly the FDA ;) must have missed the side note detailing that HGF and BDNF were among measured improvements in biomarkers. GDNF was not a prespecified measurement however a decrease in the inflammatory negative marker (MCP-1) is scientifically associated with the improvement of GDNF.   Biomarkers you say missing were not highlighted pretrial like VEGF, Improving NFL, reducing MCP-1, as are more indicative clinical benefit.   
The full Biomarker list: Fetuin-A, hsa-miR-146a-5p, hsa-miR-146b-5p, IL-37, LAP, MCP-1, MSR1, OPG, S100B, SDF-1a for Neuroinflammation; DR6, NfL, pNfH and TWEAK for Neurodegeneration; BDNF, Clusterin/ApoJ, galectin-1, G-CSF, GDF-15, HGF, NMNAT1 and VEGF for Neuroprotection; Follistatin, hsa-miR-124-3p, hsa-miR-132-3p, hsa-miR-19b-3p, hsa-miR-20a-5p, hsa-miR-30b-5p and hsa-miR-34a-5p for Other category. NfL, pNfH, hsa-miR-19b-3p and hsa-miR-20a-5p are not significant for the population with ALSFRS-R &gt; 25 at baseline.   
https://onlinelibrary.wiley.com/doi/full/10.1002/mus.28093

Wiley

You and allegedly the FDA ;) must have missed the side note detailing that HGF and BDNF were among measured improvements in biomarkers. GDNF was not a prespecified measurement however a decrease in the inflammatory negative marker (MCP-1) is scientifically associated with the improvement of GDNF.   Biomarkers you say missing were not highlighted pretrial like VEGF, Improving NFL, reducing MCP-1, as are more indicative clinical benefit.   
The full Biomarker list: Fetuin-A, hsa-miR-146a-5p, hsa-miR-146b-5p, IL-37, LAP, MCP-1, MSR1, OPG, S100B, SDF-1a for Neuroinflammation; DR6, NfL, pNfH and TWEAK for Neurodegeneration; BDNF, Clusterin/ApoJ, galectin-1, G-CSF, GDF-15, HGF, NMNAT1 and VEGF for Neuroprotection; Follistatin, hsa-miR-124-3p, hsa-miR-132-3p, hsa-miR-19b-3p, hsa-miR-20a-5p, hsa-miR-30b-5p and hsa-miR-34a-5p for Other category. NfL, pNfH, hsa-miR-19b-3p and hsa-miR-20a-5p are not significant for the population with ALSFRS-R > 25 at baseline.   
